Ned Sacktor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/167263/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment. Nature Reviews Neurology, 2016, 12, 234-248.	4.9	690
2	HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of NeuroVirology, 2002, 8, 136-142.	1.0	555
3	Human immunodeficiency virusâ€associated neurocognitive disorders: Mind the gap. Annals of Neurology, 2010, 67, 699-714.	2.8	382
4	Human Immunodeficiency Virus-Associated Dementia: An Evolving Disease. Journal of NeuroVirology, 2003, 9, 205-221.	1.0	370
5	The Epidemiology of Human Immunodeficiency Virus-Associated Neurological Disease in the Era of Highly Active Antiretroviral Therapy. Journal of NeuroVirology, 2002, 8, 115-121.	1.0	354
6	Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology, 2016, 86, 334-340.	1.5	293
7	The International HIV Dementia Scale: a new rapid screening test for HIV dementia. Aids, 2005, 19, 1367-74.	1.0	282
8	Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain Imaging and Behavior, 2011, 5, 77-85.	1.1	154
9	HIV Subtype D Is Associated with Dementia, Compared with Subtype A, in Immunosuppressed Individuals at Risk of Cognitive Impairment in Kampala, Uganda. Clinical Infectious Diseases, 2009, 49, 780-786.	2.9	129
10	Attenuated Central Nervous System Infection in Advanced HIV/AIDS With Combination Antiretroviral Therapy. Archives of Neurology, 2004, 61, 1687.	4.9	125
11	Factors affecting brain structure in men with HIV disease in the post-HAART era. Neuroradiology, 2012, 54, 113-121.	1.1	117
12	Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 696-703.	1.3	114
13	Evolution of HIV dementia with HIV infection. International Review of Psychiatry, 2008, 20, 25-31.	1.4	111
14	Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection—The Hawaii Aging with HIV Cohort. Journal of NeuroVirology, 2006, 12, 387-391.	1.0	102
15	Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Current Opinion in Neurology, 2006, 19, 358-361.	1.8	94
16	Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Annals of Neurology, 2006, 59, 237-247.	2.8	91
17	Neuropsychological test profile differences between young and old human immunodeficiency virus–positive individuals. Journal of NeuroVirology, 2007, 13, 203-209.	1.0	85
18	Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy. Aids, 2019, 33, S145-S157.	1.0	85

#	Article	IF	CITATIONS
19	Novel markers of oxidative stress in actively progressive HIV dementia. Journal of Neuroimmunology, 2004, 157, 176-184.	1.1	83
20	Changing clinical phenotypes of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2018, 24, 141-145.	1.0	83
21	White matter damage, neuroinflammation, and neuronal integrity in HAND. Journal of NeuroVirology, 2019, 25, 32-41.	1.0	77
22	Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: Protection by diosgenin and I-deprenyl. Neurobiology of Disease, 2006, 23, 109-119.	2.1	74
23	Differences in Cognitive Function Between Women and Men With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 101-107.	0.9	70
24	Pattern of neuropsychological performance among HIV positive patients in Uganda. BMC Neurology, 2007, 7, 8.	0.8	69
25	Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. Journal of NeuroVirology, 2008, 14, 362-367.	1.0	66
26	Microglial activation is inversely associated with cognition in individuals living with HIV on effective antiretroviral therapy. Aids, 2018, 32, 1661-1667.	1.0	60
27	Cohort Profile: Recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study. International Journal of Epidemiology, 2015, 44, 1506-1516.	0.9	58
28	Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Current Opinion in HIV and AIDS, 2014, 9, 517-520.	1,5	57
29	A lipid storage–like disorder contributes to cognitive decline in HIV-infected subjects. Neurology, 2013, 81, 1492-1499.	1.5	53
30	A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. Journal of Magnetic Resonance Imaging, 2005, 21, 325-333.	1.9	51
31	HIV-associated cognitive impairment in sub-Saharan Africa—the potential effect of clade diversity. Nature Clinical Practice Neurology, 2007, 3, 436-443.	2.7	49
32	A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2011, 17, 159-165.	1.0	46
33	Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 2017, 23, 369-375.	1.0	46
34	Longitudinal psychomotor speed performance in human immunodeficiency virus–seropositive individuals: impact of age and serostatus. Journal of NeuroVirology, 2010, 16, 335-341.	1.0	44
35	Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy. Aids, 2019, 33, 475-481.	1.0	44
36	Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals. Journal of NeuroVirology, 2011, 17, 382-392.	1.0	40

#	Article	IF	CITATIONS
37	Neuroprotective Therapy for HIV Dementia. Current HIV Research, 2003, 1, 373-383.	0.2	39
38	Platelet Decline. Archives of Neurology, 2007, 64, 1264.	4.9	37
39	Factor Analysis of Proton MR Spectroscopic Imaging Data in HIV Infection: Metabolite-derived Factors Help Identify Infection and Dementia. Radiology, 2010, 254, 577-586.	3.6	36
40	Peripheral neuropathy in HIV-infected and uninfected patients in Rakai, Uganda. Neurology, 2017, 89, 485-491.	1.5	36
41	Effects of comorbidity burden and age on brain integrity in HIV. Aids, 2019, 33, 1175-1185.	1.0	35
42	Reward, attention, and HIV-related risk in HIV+ individuals. Neurobiology of Disease, 2016, 92, 157-165.	2.1	34
43	Cortical brain atrophy and intra-individual variability in neuropsychological test performance in HIV disease. Brain Imaging and Behavior, 2016, 10, 640-651.	1.1	34
44	Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. Journal of NeuroVirology, 2018, 24, 16-27.	1.0	34
45	Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Therapy, 2010, 4, 371-379.	0.6	33
46	Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Future HIV Therapy, 2008, 2, 271-280.	0.5	31
47	Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States. Journal of the International Neuropsychological Society, 2018, 24, 163-175.	1.2	29
48	Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda. Journal of NeuroVirology, 2013, 19, 48-56.	1.0	28
49	Midlife adiposity predicts cognitive decline in the prospective Multicenter AIDS Cohort Study. Neurology, 2019, 93, e261-e271.	1.5	28
50	Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates. Journal of the International Neuropsychological Society, 2019, 25, 507-519.	1.2	28
51	Older individuals with HIV infection have greater memory deficits than younger individuals. Journal of NeuroVirology, 2013, 19, 531-536.	1.0	27
52	HIV disease and diabetes interact to affect brain white matter hyperintensities and cognition. Aids, 2018, 32, 1803-1810.	1.0	27
53	Genomeâ€wide association study of HIVâ€associated neurocognitive disorder (HAND): A CHARTER group study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 413-426.	1.1	26
54	Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder	7.780	25

⁽HAND): defining "symptomatic―versus "asymptomatic―HAND. Journal of NeuroVirology, 2017, 23, 67-78. 54

#	Article	IF	CITATIONS
55	Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. Journal of NeuroVirology, 2014, 20, 620-626.	1.0	24
56	Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study. Aids, 2015, 29, 713-721.	1.0	24
57	Human Immunodeficiency Virus-Associated Dementia: An Evolving Disease. Journal of NeuroVirology, 2003, 9, 205-221.	1.0	22
58	Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. Journal of Virus Eradication, 2016, 2, 243-250.	0.3	22
59	HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda. Metabolic Brain Disease, 2014, 29, 261-268.	1.4	21
60	Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 216-223.	0.9	21
61	Cross-sectional analysis of cognitive function using multivariate normative comparisons in men with HIV disease. Aids, 2019, 33, 2115-2124.	1.0	19
62	Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research. Journal of NeuroVirology, 2020, 26, 809-823.	1.0	19
63	Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 61-70.	0.9	18
64	A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder. Journal of NeuroVirology, 2013, 19, 432-441.	1.0	17
65	Visceral fat is associated with brain structure independent of human immunodeficiency virus infection status. Journal of NeuroVirology, 2017, 23, 385-393.	1.0	16
66	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	2.1	15
67	Association of Marijuana Use with Changes in Cognitive Processing Speed and Flexibility for 17 Years in HIV-Seropositive and HIV-Seronegative Men. Substance Use and Misuse, 2019, 54, 525-537.	0.7	15
68	Use of Neuroimaging to Inform Optimal Neurocognitive Criteria for Detecting HIV-Associated Brain Abnormalities. Journal of the International Neuropsychological Society, 2020, 26, 147-162.	1.2	15
69	Beta-amyloid (Aβ) uptake by PET imaging in older HIV+ and HIV- individuals. Journal of NeuroVirology, 2020, 26, 382-390.	1.0	15
70	Neuropsychological phenotypes among men with and without HIV disease in the multicenter AIDS cohort study. Aids, 2018, 32, 1679-1688.	1.0	14
71	Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda. Journal of NeuroVirology, 2019, 25, 800-813.	1.0	14
72	Exploring the relationship of macrophage colony-stimulating factor levels on neuroaxonal metabolism and cognition during chronic human immunodeficiency virus infection. Journal of NeuroVirology, 2010, 16, 368-376.	1.0	13

#	Article	IF	CITATIONS
73	7T Brain MRS in HIV Infection: Correlation with Cognitive Impairment and Performance on Neuropsychological Tests. American Journal of Neuroradiology, 2018, 39, 704-712.	1.2	13
74	Brain structural correlates of trajectories to cognitive impairment in men with and without HIV disease. Brain Imaging and Behavior, 2020, 14, 821-829.	1.1	13
75	Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV. Annals of Clinical and Translational Neurology, 2020, 7, 1166-1173.	1.7	12
76	Interleukin-6 is associated with mortality and neuropsychiatric outcomes in antiretroviral-naÃ ⁻ ve adults in Rakai, Uganda. Journal of NeuroVirology, 2019, 25, 735-740.	1.0	11
77	Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1–Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings. Clinical Infectious Diseases, 2020, 71, 158-165.	2.9	10
78	Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. Neurology, 2019, 92, e1344-e1353.	1.5	9
79	Sex-specific associations between cerebrospinal fluid inflammatory marker levels and cognitive function in antiretroviral treated people living with HIV in rural Uganda. Brain, Behavior, and Immunity, 2021, 93, 111-118.	2.0	9
80	Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. Aids, 2017, 31, 1365-1378.	1.0	8
81	Headache prevalence and its functional impact among HIV-infected adults in rural Rakai District, Uganda. Journal of NeuroVirology, 2019, 25, 248-253.	1.0	8
82	Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 534-542.	0.9	8
83	Cognitive Impairment Among Older Individuals with HIV Infection. Current Geriatrics Reports, 2016, 5, 63-70.	1.1	7
84	Neuropsychological changes in efavirenz switch regimens. Aids, 2019, 33, 1307-1314.	1.0	7
85	The BIOCARD Index. Alzheimer Disease and Associated Disorders, 2017, 31, 114-119.	0.6	6
86	CCL3L1 gene copy number in individuals with and without HIV-associated neurocognitive disorder. Current Biomarker Findings, 2012, 2012, 1.	0.4	5
87	Vitamin D is not associated with HIV-associated neurocognitive disorder in Rakai, Uganda. Journal of NeuroVirology, 2019, 25, 410-414.	1.0	5
88	Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Disorder. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 278-283.	0.9	4
89	Intraindividual variability in neurocognitive performance: No influence due to HIV status or self-reported effort. Journal of Clinical and Experimental Neuropsychology, 2018, 40, 1044-1049.	0.8	3
90	The Veterans Aging Cohort Study Index is not associated with HIV-associated neurocognitive disorders in Uganda. Journal of NeuroVirology, 2020, 26, 252-256.	1.0	3

#	Article	IF	CITATIONS
91	Association of midlife smoking status with change in processing speed and mental flexibility among HIV-seropositive and HIV-seronegative older men: the Multicenter AIDS Cohort Study. Journal of NeuroVirology, 2017, 23, 239-249.	1.0	2
92	Caregiver versus self-reported activities of daily living among HIV-positive persons in Rakai, Uganda. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 836-839.	0.6	2
93	Assessment, prevalence, and correlates of frailty among middle-aged adults with HIV in rural Uganda. Journal of NeuroVirology, 2021, 27, 487-492.	1.0	2
94	Evaluation of a screening tool for the identification of neurological disorders in rural Uganda. Journal of the Neurological Sciences, 2021, 421, 117273.	0.3	1
95	Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda. Journal of NeuroVirology, 2021, 27, 519-530.	1.0	1
96	Neuropathic pain correlates with worsening cognition in people with human immunodeficiency virus. Brain, 2022, 145, 2206-2213.	3.7	1
97	Human Immunodeficiency Virusâ€Associated Dementia: Clinical Aspects, Biology, and Treatment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 799-806.	1.0	0
98	Neurocognitive Complications of HIV Infection in Low-Income Countries. Current Topics in Behavioral Neurosciences, 2019, 50, 225-244.	0.8	0
99	Letter to the Editor. Journal of NeuroVirology, 2019, 25, 897-898.	1.0	0